The Japanese Gynecologic Oncology Group is currently conducting a basket trial on niraparib monotherapy for any gynecological cancer (except ovarian cancer) with BRCA1/2 genomic alterations, which targets a rare fraction of each cancer type [38]. This evidence concerns the gene BRCA1 and ovarian cancer.